Action Behavior Centers – ABA Therapy for Autism (ABC) is the largest and one of the leading national providers of pediatric applied behavior analysis (ABA) therapy, with more than 30 locations in Colorado. At ABC, children with autism benefit from one-on-one support from energetic and highly-trained clinicians. Together with families, these professionals set individual goals that honor each child’s unique way of learning and communicating. ABC works directly with the communities we serve to address disparities in access to autism services by offering immediate availability for autism diagnostic evaluations, in addition to evidence-based and assent-based therapies through our “No Waitlist” policy. Together, we are able to further our mission of helping children with autism reach milestone moments. We look forward to connecting with you to share how we can support your patients and our local pediatric community through the highest quality of compassionate care, accessibility, and convenience for you, your patients, and their families. Contact: Andrea Delgado, (956) 624-4825, andrea.delgado@actionbehavior.com.

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.  Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide.  For more information, please visit www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.

Autism Learning Partners (ALP) is an ABA industry leader and nationwide provider in evidence-based, family-oriented autism therapies. For over 30 years, ALP has been specializing in the treatment of developmental disabilities while providing customized care plans for individuals with autism and their family. Support is provided in a variety of settings including in-center, in-home, school, and community. ALP collaborates with local community partners such as doctors, therapists, families, schools and specialists for comprehensive, effective care. Our goal is to work together to achieve the best possible outcome for each child. We accept most major insurance plans, including Medicaid. We provide services in English, Spanish, and more upon request. Visit our website at www.AutismLearningPartners.com or email us at Intake@AutismLearningPartners.com.

The Colorado Immunization Branch, at the Colorado Department of Public Health and Environment, works to reduce vaccine-preventable disease by developing and implementing programs designed to positively influence the uptake of immunizations across the lifespan. The Immunization Branch utilizes a variety of strategies to promote education, optimize vaccine resources, assure access to vaccines and maintain the Colorado Immunization Information System (CIIS), a confidential, population-based, computerized information system that collects and consolidates immunization data for Coloradans of all ages from a variety of sources and provides tools for designing and sustaining effective immunization strategies at the provider and program levels. The Immunization Branch also operates the Federal Vaccines for Children (VFC) program, the Federal Section 317 program, and all immunization education and outreach activities. Learn more by visiting the organization’s website here.

The Colorado Newborn Bloodspot Screening Program (CONBSP) aims to improve newborn’s lives through early detection of 39 life threatening genetic disorders for all Colorado and Wyoming newborns. CONBSP initially began testing for Phenylketonuria (PKU) in 1965.  Annually, there are approximately 68,000 births in Colorado and Wyoming. Currently, there are requests that come from over 800 unique submitters. This translates into reporting more than 130,000 samples using 9 different testing methods for more than 700,000 individual tests annually. There are 700 affected children identified each year due to this testing. The CONBSP is required by statute to operate 6 days a week including holidays in order to ensure timely reporting of abnormal results. Babies with these conditions often appear normal at birth but could develop signs and symptoms later in life. CONBSP performs screening tests for all newborns on an opt out basis. All testing, reporting, education, and stakeholder engagement is performed by 21 full-time staff members. The program is cash funded provided by a one-time fee of $111.00 for each child tested. The program is a part of the Colorado State Public Health Laboratory within the Division of Disease Control and Public Health Response (DCPHR) at CDPHE.